Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AEC/BC02 Phase Ib in Healthy Adults
NCT04239313Phase 1Completed
- Sponsor
- Zhifei Biological
- Start
- May 2020
- Primary completion
- Feb 2021
- Modality
- Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of AEC/BC02 in Tuberculosis (TB) (3 arms), sponsored by Zhifei Biological. Primary endpoint: Number of adverse events after intramuscular injection. Started May 2020; status: completed.
02
Drugs
AEC/BC02
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT04239313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04239313.